Evaluation of Anticonvulsant Activity of Dual COX-2/5-LOX Inhibitor Darbufelon and Its Novel Analogues

Mariia Mishchenko 1, Sergiy Shtrygol 1, Andrii Lozynskyi 2, Semen Khomyak 3, Volodymyr Novikov 3, Alexandr Karpenko 4, Serhii Holota 2,5 and Roman Lesyk 2,6,*

1 Department of Pharmacology and Pharmacotherapy, National University of Pharmacy, 53 Pushkinska, 61002 Kharkiv, Ukraine; farmacol@nuph.edu.ua (M.M.); shtrygol@ukr.net (S.S.)
2 Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Hal’ytsky Lviv National Medical University, 69 Pekarska, 79010 Lviv, Ukraine; lozynskyiandrii@gmail.com (A.L.); golota_serg@yahoo.com (S.H.)
3 Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Polytechnic National University,12 Bandery, 79013 Lviv, Ukraine; semen.v.khomyak@lpnu.ua (S.K.); vnovikov@polynet.liviu.ua (V.N.)
4 Enamine Ltd., 23 Alexandra Matrosova, 01103 Kiev, Ukraine; karalexander@gmail.com
5 Department of Organic Chemistry and Pharmacy, Lesya Ukrainka Volyn National University, Volya Avenue 13, 43025 Lutsk, Ukraine
6 Department of Public Health, Dietetics and Lifestyle Disorders, Faculty of Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225 Rzeszow, Poland
* Correspondence: dr_r_lesyk@org.liviu.net; Tel.: +38-(032)-275-5966

Abstract: Neuroinflammation is an integral part of epilepsy pathogenesis and other convulsive conditions, and non-steroidal anti-inflammatory drugs (NSAIDs) present a potent tool for the contemporary search and design of novel anticonvulsants. In the present paper, evaluation of the anticonvulsant activity of the potential NSAID dual COX-2/5-LOX inhibitor darbufelon methanesulfonate using an scPTZ model in mice in dose 100 mg/kg is reported. Darbufelon possesses anticonvulsant properties in the scPTZ model and presents interest for in-depth studies as a possible anticonvulsant multi-target agent with anti-inflammatory activity. The series of 4-thiazolidinone derivatives have been synthesized following the analogue-based drug design and hybrid-pharmacophore approach using a darbufelon matrix. The synthesized derivatives showed a significant protection level for animals in the scPTZ model and are promising compounds for the design of potential anticonvulsants with satisfactory drug-like parameters.

Keywords: 4-thiazolidinones; darbufelon; dual COX-2/5-LOX inhibitor; pentylenetetrazole seizure; anticonvulsant activity

1. Introduction

More than 70 million people suffer from epilepsy and seizure conditions, constituting nearly 1% of the global population [1]. The available schemes and protocols for the treatment of such pathologies are very often imperfect, therefore the research and development of innovative anticonvulsants are unmet and actual problems for medicinal chemists [2–5]. Recently, considerable attention in search of possible targets for the correction of epilepsy and related conditions has been focused on the neuroinflammation process which occurs due to many reasons, such as neuroinfection, strokes, and head injuries, and can initiate an inflammatory cascade in the central nervous system [6,7]. Neuroinflammation is a predictor of increased convulsive readiness [8] and key trigger for epilepsy pathogenic mechanisms such as the activation of microglia and microglial inflammatory mediators [9], the expression of circulating immune cells [10], cytokine and chemokine upregulation [11], free radical formation [12], and cyclooxygenases-1 and 2 (COX-1/2) upregulation, etc. [13,14]. Therefore, potential NSAIDs with different mechanisms of action
represent a powerful tool for modern anticonvulsant design [15,16]. A number of approved NSAIDs from many chemical chemotypes were evaluated in various screening convulsive models and were found to be effective, as well as prospects for subsequent experiments (Figure 1) [17–22].

Both primary enzymes COX-1 and COX-2, which catalyze the synthesis of inflammatory prostanoids and are main targets for NSAIDs, have been reported as potential neurotherapeutic targets for epilepsy correction and management [14,16,23].

In the aforementioned context, the darbufelone–NSAID, a dual inhibitor targeting COX-2 and 5-lipoxygenase (5-LOX), presents interest for study as a possible potential anticonvulsant. Darbufelone belongs to 4-thiazolidinone derivatives, and among this class of heterocycles, the thiazole-4-thiazolidinone hybrid molecules are known as an important source of drug-like molecules with various kinds of biological activities as well as polypharmacological agents [24–29]. The thiazole-4-thiazolidinone-bearing hybrids with promising anticonvulsant properties were identified and reported [26,30]. Among them the hit-compound Les-6222 (Figure 2) was found to be the most active in maximal electroshock seizures (MES) and pentylenetetrazole (PTZ) tests, and at doses of 50–150 mg/kg possessed equal activity compared to sodium valproate and carbamazepine.

Taking into account all the above reasons, herein we present a study of the anticonvulsant properties of darbufelon in a subcutaneous pentylenetetrazole (scPTZ) seizure model. Additionally, as a logical continuation, the other main goal of the current work was the synthesis of some darbufelon analogues and hybrids with thiazole moieties (Figure 2) and the evaluation of their anticonvulsant activity in scPTZ tests.

**Non-selective COX inhibitors**

| Compound | Activity |
|----------|----------|
| Paracetamol | Activity in MES-/PTZ-seizure tests; Activity in corneal ES-/PTZ-kindling models [17] |
| Diclofenac | Activity in PTZ-kindling model [18] |
| Naproxen | Activity in PTZ-induced seizure/kindling models [21] |

| Compound | Activity |
|----------|----------|
| Rofecoxib | Activity in PTZ-induced seizure test [19] |
| Celecoxib | Activity in autosomal dominant lateral temporal epilepsy [20] |
| Meloxicam | Activity in MES-/PTZ-seizure tests [22] |

**Selective COX-2 inhibitors**

Figure 1. Anticonvulsant properties of marketed NSAIDs.
2. Materials and Methods

2.1. General Information

All materials were purchased from commercial sources and used without purification. Melting points were measured in open capillary tubes and are uncorrected. The elemental analyses (C, H, N) were performed using the Perkin–Elmer 2400 CHN analyzer (Perkin–Elmer, Norwalk, CT, USA) and were within 0.4% of the theoretical values. The $^1$H and $^{13}$C NMR spectra were recorded on a Bruker AVANCE–400 spectrometer (Bruker, Bremen, Germany). All spectra were recorded at room temperature, except where indicated otherwise, and were referenced internally to solvent reference frequencies. Chemical shifts (δ) are quoted in ppm, and coupling constants (J) are reported in Hz. LC–MS spectra were obtained on a Finnigan MAT INCOS-50 (Thermo Finnigan LLC, San Jose, CA, USA). Solvents and reagents that are commercially available were used without further purification.

The procedure used for the synthesis of compound 1b was described in [31]; for compounds 3a,b, in [32]. The derivatives Les-6290, Les-6291, Les-6296 have been obtained from 3a,b and 2-aminothiazol-4(5H)-one (4) accordingly to the protocol described in [33].

2.2. Synthesis and Characterization of Compounds

2.2.1. Synthesis of (thiazol-2-ylamino/5-acetyl-4-methyl-thiazol-2-ylamino)-acetyl chlorides (2a,b)

A solution of chloroacetyl chloride (3 mmol) in 5 mL of dioxane was added to an appropriate mixture of 2-aminothiazole (1a) or 2-amino-4-methyl-5-acetylthiazole (1b) (3 mmol) and triethylamine (3 mmol) in 5 mL of dioxane and was later heated to 70–80 °C for 30 min, cooled, and poured into water (50 mL). The obtained powder was filtered off, washed with water, and recrystallized from ethanol.

2.2.2. Characterization of Compounds Les-6296, Les-6290, Les-6291

Les-6296: 5-(3,5-Di-tert-butyl-4-hydroxybenzylidene)-2-(thiazol-2-ylimino)-thiazolidin-4-one. Yield 72%, yellow-brown powder, m.p. 170–172 °C; $^1$H NMR (400 MHz, DMSO-$d_6$): δ 1.39, 1.41 (2s, 18H, t-Bu), 7.38 (m, 1H, thiazol.), 7.45 (s, 1H, =CH), 7.60 (m, 1H, thiazol.), 7.64 (m, 2H, arom.), 8.00 (s, 1H, OH), 9.80, 12.21, 12.51 (3s, 1H, NH); $^{13}$C NMR (100 MHz, DMSO-$d_6$): 30.3, 34.8, 117.6, 125.1, 127.3, 128.7, 133.7, 140.3, 144.6, 148.0, 162.7, 168.6, 192.4. Anal. Calcd for C$_{21}$H$_{25}$N$_2$O$_5$S$_2$: C, 60.69; H, 6.06; N, 10.11. Found: C, 60.60; H, 6.00; N, 10.19. ESI-MS m/z 416 (M+H)$^+$.  

Figure 2. Background and design for the current work.
Les-6290: 2-(5-Acetyl-4-methylthiazol-2-ylimino)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-thiazolidin-4-one. Yield 80%, yellow-brown powder, m.p. 158–160 °C; $^1$H NMR (400 MHz, DMSO-$d_6$): $\delta$ 1.26 (s, 3H, CH$_3$), 1.39 (s, 18H, t-Bu), 1.51 (s, 3H, CH$_3$), 7.38, 7.45 (2*s, 1H, =CH), 7.66 (s, 2H, arom.), 7.99 (s, 1H, OH), 9.80 (s, 1H, NH); $^{13}$C NMR (100 MHz, DMSO-$d_6$): 19.0, 35.0, 35.2, 39.6, 114.9, 123.5, 130.5, 132.0, 133.4, 143.8, 153.5, 165.1, 168.7, 174.5, 197.2. Anal. Calcd for C$_{24}$H$_{29}$N$_3$O$_3$S$_2$: C, 61.12; H, 6.20; N, 8.91. Found: C, 61.20; H, 6.30; N, 8.82. ESI-MS $m/z$ 472 (M+H)$^+$. 

Les-6291: 2-Amino-5-(4-nitrobenzylidene)-thiazol-4-one. Yield 80%, yellow powder, m.p. > 240 °C; $^1$H NMR (400 MHz, DMSO-$d_6$): $\delta$ 7.68 (s, 1H, =CH), 7.81 (d, 2H, $J$ = 8.5 Hz, arom.), 8.32 (d, 2H, $J$ = 8.5 Hz, arom.), 9.34, 9.62 (2*s, 2H, NH$_2$); $^{13}$C NMR (100 MHz, DMSO-$d_6$): 129.4, 131.6, 135.4, 139.0, 145.8, 152.1, 180.3, 185.0. Anal. Calcd for C$_{10}$H$_7$N$_3$O$_3$S: C, 48.00; H, 3.22; N, 16.70. Found: C, 48.07; H, 3.32; N, 16.80. ESI-MS $m/z$ 250 (M+H)$^+$. 

2.3. Pharmacology Assay

2.3.1. Animals

The experiments were conducted on random-bred male albino mice weighing 18–22 g purchased from the Animal House of the Central Research Laboratory of the Educational and Scientific Institute of Applied Pharmacy of the National University of Pharmacy, Kharkiv, Ukraine. The animals were housed in groups of 10 in standard plastic cages, at room temperature of 20 ± 2 °C, exposed to a 12:12 h light/dark cycle, with ad libitum standard laboratory food and water. All experiments were performed between 9 a.m. and 3 p.m. The tested groups consisting of 6–7 mice were chosen by means of a randomized schedule. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted, and were approved by the Local Ethical Committee in National University of Pharmacy, Kharkiv, Ukraine (Approval No: 3/2019).

2.3.2. Subcutaneous Pentylenetetrazole Model (scPTZ)

The scPTZ-induced seizures were performed by subcutaneous injection of PTZ (90 mg/kg). Animals were placed into the separate transparent plastic cylindrical containers and continuously monitored for 60 min. Sodium valproate (Depakine, Sanofi-Aventis, France) at a dose of 300 mg/kg [34] in the form of a syrup for oral administration, and phenytoin (Diphenin, Kyiv Vitamin Plant, Kyiv City, Ukraine) at a dose of 40 mg/kg [35] were used as reference drugs. Celecoxib (Celebrex, Pfizer, New York City, NY, USA)—selective COX-2 inhibitor with early described anticonvulsant properties [36] was used at a dose of 4 mg/kg for comparison. Darbufelone methanesulfonate and compounds Les-6290, Les-6291, and Les-6296 were administered once intragastrically (i.g.) in the form of an aqueous suspension stabilized with Tween-80 at a dose of 100 mg/kg 30 min before seizure induction [34]. The dose of test compounds at 100 mg/kg was selected for this screening study based on previous studies of a number of 4-thiazolidinone derivatives, in which the compounds showed a pronounced anticonvulsant effect [26,30]. The Les-6296 was further tested at a dose of 75 mg/kg (i.g.), which is equivalent to a dose of 100 mg/kg of darbufelone methanesulfonate. The Les-6291 was also administered i.g. at a dose of 53 mg/kg, which corresponds to a 40 mg/kg dose of phenytoin. The effectiveness of all substances were evaluated by the following indicators: latency period of first convulsions (latency), the number of clonic–tonic seizures in 1 mouse, percentage of animals in the group separately with clonic and tonic convulsions, severity of seizure—in points (1 point—single tremors; 2 points—“manege” running or “kangaroo” position; 3 points—clonic convulsions without lateral position; 4 points—clonic–tonic convulsions with lateral position; 5 points—tonic extension; 6 points—tonic extension, which led to the death of the animal), duration of convulsive period (period of seizures), life expectancy of animals to death (time to death), and lethality. If seizures were not observed for 1 h, the latency was considered to be 60 min [37]. For statistical analysis, STATISTICA 12.0 for Windows was used. Data are reported as the mean ± standard error of mean (mean ± SEM).
The level of statistical significance was considered as $p < 0.05$. Statistical differences between groups were analyzed using the parametric Student’s $t$-test in cases of normal distribution; nonparametric Mann–Whitney U-tests in its absence. For the results in the alternative form (lethality, percentage of mice with clonic and tonic convulsions) the Fisher’s angular transformation (with Yates’s correction, if necessary) was used.

3. Results and Discussion

3.1. Chemical Synthesis and Drug-Likeness Properties

The general synthetic strategy of the present work included two approaches for target thiazole–4-thiazolidinone hybrids and darbufelone analogues: (1) based on a 4-thiazolidinone core formation with the next modification at the C-5 position of heterocycle (Scheme 1A); and (2) using of ready cyclic precursor (4) for modification at the C-5 position following Knoevenagel condensation (Scheme 1B).

Initially, N-(thiazol-2-yl)- and N-(5-acetyl-4-methylthiazol-2-yl) 2-chloroacetamides (2a,b) were obtained from the appropriate aminothiazoles 1a,b (Scheme 1A). The aforementioned acylation reaction was performed under reflux for 30 min due to weak reactivity of the amino groups of the compounds 1a,b. Synthesized derivatives 2a,b were utilized as equivalents of dielectrophilic synthons $[C_2]^2+$ in the [2+3]-cyclocondensation reaction with ammonium thiocyanate in acetone providing the appropriate thiazole-bearing 4-thiazolidinones 3a,b. Subsequently, compounds 3a,b, and 4 were transformed in the Knoevenagel reaction (medium—glacial acetic acid; catalyst—anhydrous sodium acetate) to obtain the target hybrids Les-6290, Les-6291, Les-6296 (Scheme 1A,B).

The compound structures were characterized and confirmed using $^1$H, $^1$C NMR, and LC–MS spectra.

The physicochemical properties of the darbufelon and derivatives Les-6290, Les-6291, and Les-6296 were determined based on Lipinski and Veber rules using the SwisAdme of Swiss Institute of Bioinformatics website [38] (Table 1).
Table 1. Drug-likeness parameters of the darbufelor and derivatives Les-6290, Les-6291, and Les-6296 according to Lipinski and Veber rules.

| Compounds/Drugs   | MW ≤ 500 | Log P ≤ 5 | NHD ≤ 5 | NHA ≤ 10 | NBR ≤ 10 | TPSA ≤ 140 | Violations of Rules |
|-------------------|----------|-----------|---------|----------|----------|-----------|-------------------|
| Darbufelor        | 332.46   | 2.88      | 2       | 3        | 3        | 100.98    | 0                 |
| Les-6290          | 471.64   | 3.81      | 2       | 5        | 6        | 145.19    | 1                 |
| Les-6291          | 249.25   | 1.19      | 1       | 4        | 2        | 126.57    | 0                 |
| Les-6296          | 415.57   | 3.41      | 2       | 4        | 5        | 128.12    | 0                 |

NHD: number of hydrogen bond donors; NHA: number of hydrogen acceptors; NBR: number of rotatable bonds; TPSA: total polar surface area.

All tested compounds complied with Lipinski’s rule of five. Meanwhile, derivative Les-6290 had a total polar surface area value higher (145.16, accordingly) than limited (≤ 140), in line with Veber’s rules.

3.2. Anticonvulsant Activity of Synthesized Compounds

The anticonvulsant activity of darbufelor and derivatives Les-6290, Les-6291, and Les-6296 were evaluated using an scPTZ test and studies results are presented in Figure 1 and Table 2. The reference drug, sodium valproate, showed an expressive anticonvulsant effect, maximally preventing seizures in animals. Meanwhile, the other reference drug, phenytoin, at a dose of 40 mg/kg, affected only the latent period of seizures, and increased them 1.73-fold. Additionally, the phenytoin impact on lethality decrease was inexpressive (only 19%), which could be explained by the predominant blocking of potential-dependent sodium channels [37], i.e., insufficient compliance of the PTZ-induced seizure mechanism.

Table 2. Anticonvulsant activity of the reference drugs, celecoxib, dual COX-2/5-LOX inhibitor darbufelor methanesulfonate and derivatives Les-6290, and Les-6291, Les-6296 in the scPTZ test. Each value represents the mean ± S.E.M. obtained from 6 mice.

| Group of Animals | Dose, mg/kg | Number of Clonic-Tonic Seizures per Mouse | Mice with Seizures, % | Seizure Severity, Points | Lethality, % |
|------------------|-------------|------------------------------------------|-----------------------|--------------------------|--------------|
|                  |             |                                          | Clonic                | Tonic                    |              |
| CP(PTZ)          | 90          | 2.29 ± 0.52                              | 100                   | 85.71                    | 5.57 ± 0.43  | 85.71        |
| SV               | 300         | 0.00 ± 0.00**                            | 0 **                  | 0 **                     | 0 **         |              |
| PHT              | 40          | 1.17 ± 0.17                              | 100                   | 66.67                    | 5.00 ± 0.63  | 66.67        |
| CXB              | 4           | 2.00 ± 0.37                              | 100                   | 66.67                    | 4.67 ± 0.62  | 50.00        |
| DAR              | 100         | 1.17 ± 0.17                              | 100                   | 50.00                    | 3.67 ± 0.84 *| 16.67 **     |
| Les-6290         | 100         | 1.67 ± 0.56                              | 83.33 **              | 50.00                    | 3.67 ± 0.84 *| 16.67 **     |
| Les-6291         | 53          | 1.00 ± 0.63                              | 50.00 **              | 33.33 *                  | 2.50 ± 1.20  | 33.33 *      |
| Les-6296         | 75          | 0.83 ± 0.17                              | 83.33 **              | 16.67 **                 | 2.67 ± 0.56  | 0.00 **      |

CP(PTZ), control pathology; SV, sodium valproate; PHT, phenytoin; CXB, celecoxib; DAR, darbufelor methanesulfonate; * p < 0.05; ** p < 0.01 compared to the group control pathology (CP(PTZ)).

The administration of the selective COX-2 inhibitor celecoxib at a dose of 4 mg/kg resulted in a moderate anticonvulsant activity in the scPTZ test. In the experimental conditions, by treatment of celecoxib, the proportion of animals with tonic seizures insiginificantly reduced (at 19.04%); the animal lethality decreased (at 35.71%); and the period of latency was equal compared to the control pathology (PTZ)(CP(PTZ)) group.

Meanwhile, the administration of dual COX-2/5-LOX inhibitor darbufelor methanesulfonate at a dose of 100 mg/kg resulted in prolonging the latency 2.3-fold, reducing the severity of the seizures (at 28.18%), reducing the length of the seizure period by 9.76-fold, and showed an absolute protective effect on lethality (0%) compared to the CP(PTZ)-group. Additionally, the administration of darbufelor methanesulfonate led to prolonging the latency period by 2.09-fold and reducing the duration of the convulsive period by 7.86-fold in comparison with the animal group which received celecoxib. Considering the more pronounced anticonvulsant effect of darbufelor methanesulfonate, it is logical to
assume that both prostaglandins and leukotrienes play an important role in the mechanism of convulsive syndrome. Thus, dual impact on COX-2/5-LOX could be a more effective component for the presence of anticonvulsant effect than only the inhibition of prostaglandins synthesis.

The administration of Les-6291 at a dose of 100 mg/kg ($p < 0.05$) led to reducing the number of paroxysms per one animal by 2.29-fold. Additionally, the duration of the convulsive period was significantly reduced compared to both the CP(PTZ) group ($p < 0.01$) and the phenytoin group ($p < 0.05$). The life expectancy of animals to death was significantly ($p < 0.05$) reduced by 4.49-fold. However, the lethality to animals decreased, to 52.38% ($p < 0.05$). After the administration of the compound Les-6291 at a dose of 53 mg/kg (equivalent to a dose of 40 mg/kg of phenytoin), the latency period of the first convulsions was significantly ($p < 0.01$) increased by 7.36-fold; the number of clonic and tonic paroxysms was reduced to 50% and 52.38% accordingly, as well as the reduced severity of seizures (by 2.23-fold) and lethality (52.38%).

The derivative Les-6291 possessed anticonvulsant activity at both the used doses (100 and 53 mg/kg). A reduced number of animals with clonic seizures at 16.67%, and also reduced the number of mice with tonic convulsions compare with the CP (PTZ) group. Additionally, the administration of Les-6290 significantly reduced the number of animals with the most dangerous tonic seizures at 50% ($p < 0.01$), and at 16.67% with clonic seizures compared to the data obtained in the current experiment for the darbufelone-treated group. The severity of seizures statistically ($p < 0.05$) decreased by 1.52-fold, and lethality decreased to 69.04% compared with the CP(PTZ) group after administration of the compound Les-6290.

The compound Les-6296 was found to be the most potent in the experiment and showed expressive anticonvulsant activity at both doses (100 and 75 mg/kg), which was equivalent to a dose of darbufelone methanesulfonate. The administration of Les-6296 at both mentioned doses promoted full animal survival, reduced the seizure duration period, and reduced the severity of paroxysms. The use of compound Les-6296 (at a dose of 100 mg/kg) significantly ($p < 0.05$) led to a reduced number of animals with tonic convulsions. Meanwhile, administration at a dose of 75 mg/kg reduced the percentage of animals both with tonic (at 69.04%) and with clonic (at 16.67%) convulsions compared with the CP(PTZ) group. Additionally, compound Les-6296 in both administration doses reduced the percentage of animals with both clonic and tonic paroxysms and showed an absolute protective effect against lethality (0%) compared with the group treated with darbufelone.

It should be noted that the action of compounds Les-6290 and Les-6291 reduced the time to death at a dose of 100 mg/kg (Figure 3C). This observation does not mean that these compounds increase the risk of death, because, as shown in Table 2, they reduced the severity of seizures and significantly reduced the integral indicator—mortality. In particular, only one and two mice, from six in each group, died under the administration of compounds Les-6290 and Les-6291, respectively. Additionally, just these mentioned individual animals were characterized with convulsive syndrome which was more severe than in other animals. This led to fairly rapid death, the time of which did not exceed the fluctuations of the corresponding indicator of other groups. In the other animals treated with Les-6290 and Les-6291, the seizures stopped fairly quickly.
In a series of darbufelone and synthesized 4-thiazolidinone hybrids/analogues, the following sequence of decreasing anticonvulsant activity potency was observed: Les-6296 (75 mg/kg) > darbufelone methanesulfonate (100 mg/kg) > Les-6296 (100 mg/kg) > Les-6290 (100 mg/kg) > Les-6291 (53 mg/kg and 100 mg/kg). From the structure–activity relationship, it should be noted that presence of the thiazol-2-y1-amine substituent at position C-2 and 3,5-di-tert-butyl-4-hydroxybenzylidene moiety in position C-5 into 4-thiazolidinone molecule are optimal for anticonvulsant effects.

In this study, it was established that the selective COX-2 inhibitor celecoxib, dual COX-2/5-LOX inhibitor darbufelone methanesulfonate, and its derivatives, significantly reduced scPTZ-induced seizures in mice. The remarkable role of neuroinflammation in epileptogenesis was confirmed [6–8]. Therefore, anti-inflammatory agents would make a significant contribution to reductions in the progression of seizures in various experimental models [15–19]. The moderate protective effect of celecoxib has been confirmed in our study, which corresponds with literature data about the protective role of COX-2 inhibitors in the PTZ models [20,36,39]. This stimulates further research in the synthesis of new anticonvulsants with anti-inflammatory properties, especially among 4-thiazolidinones with polypharmacological properties.

Figure 3. Anticonvulsant activity of the reference drugs, celecoxib, dual COX-2/5-LOX inhibitor darbufelone methanesulfonate and derivatives Les-6290, Les-6291, and Les-6296 in the scPTZ test: (A) latency to the first seizure episode; (B) duration (period) of seizures; (C) time to death. Each value represents the mean ± S.E.M obtained from 6 mice. CP(PTZ), control pathology; SV, sodium valproate; PHT, phenytoin; CXB, celecoxib; DAR, darbufelone methanesulfonate; * p < 0.05; ** p < 0.01 compared to the group control pathology (CP (PTZ)).
4. Conclusions

In the present work, anticonvulsant activity screening study of dual COX-2/5-LOX inhibitor darbufelone methanesulfonate, as well as the design and synthesis of structural analogues of darbufelone, and evaluation of their anticonvulsant properties were described. Darbufelone possesses anticonvulsant properties in the scPTZ model in mice at doses of 100 mg/kg and presents interest for in-depth studies as a possible anticonvulsant multi-target agent with anti-inflammatory activity. Structure analogues/hybrids of darbufelone with thiazole moieties at position C-2 of the basic molecule, especially compound Les-6296, demonstrated a significant protection level for animals in the scPTZ model, which was equal to or more potent than for darbufelone alone. The described structure analogues/hybrids of darbufelone with thiazole moieties are promising compounds for the design of potential anticonvulsants with satisfactory drug-like parameters.

Author Contributions: Conceptualization, S.S. and R.L.; Methodology and experimental work, M.M., S.H., O.K. and S.K.; Data Analysis, S.S., S.H., A.L. and R.L.; writing—review and editing, M.M., S.S., A.L., S.H. and R.L.; Project administration and Supervision, S.S., R.L. and V.N. All authors have read and agreed to the published version of the manuscript.

Funding: The research leading to these results has received funding from the Ministry of Health of Ukraine, under the project numbers: 0121U100690, 0120U102460, and the National Research Foundation of Ukraine, under the project number: 2020.02/0035.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethic Committee of the National University of Pharmacy, Ukraine (protocol No. 3 from 20 March 2019).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in this article.

Acknowledgments: This research was supported by the Danylo Halytsky Lviv National Medical University, which is gratefully acknowledged.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Thijs, R.D.; Surges, R.; O’Brien, T.J.; Sander, J.W. Epilepsy in adults. Lancet 2019, 393, 689–701. [CrossRef]
2. Wahab, A. Difficulties in treatment and management of epilepsy and challenges in new drug development. Pharmaceuticals 2010, 3, 2090–2110. [CrossRef]
3. Dalic, L.; Cook, M.J. Managing drug-resistant epilepsy: Challenges and solutions. Neuropsychiatr. Dis. Treat. 2016, 12, 2605–2616. [CrossRef]
4. Johnson, A.B.; Kaminski, R.M. A systems-level framework for anti-epilepsy drug discovery. Neuropharmacology 2020, 170, 107868. [CrossRef]
5. Wang, Y.; Chen, Z. An update for epilepsy research and antiepileptic drug development: Toward precise circuit therapy. Pharmacol. Ther. 2019, 201, 77–93. [CrossRef] [PubMed]
6. Barker-Haliski, M.L.; Löschner, W.; White, H.S.; Galanopoulou, A.S. Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy. Epilepsia 2017, 58, 39–47. [CrossRef]
7. Vezzani, A.; Balosso, S.; Ravizza, T. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy. Nat. Rev. Neurol. 2019, 15, 459–472. [CrossRef] [PubMed]
8. Kleen, J.K.; Holmes, G.L. Brain inflammation initiates seizures. Nat. Med. 2008, 14, 1309–1310. [CrossRef] [PubMed]
9. Cai, Z.; Hussain, M.D.; Yan, L.J. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer’s disease. Int. J. Neurosci. 2014, 124, 307–321. [CrossRef] [PubMed]
10. Kleinevieffeld, M.; Hafler, D.A. Regulatory T cells in autoimmune neuroinflammation. Immunol. Rev. 2014, 259, 231–244. [CrossRef] [PubMed]
11. Becher, B.; Spath, S.; Goverman, J. Cytokine networks in neuroinflammation. Nat. Rev. Immunol. 2017, 17, 49–59. [CrossRef]
12. Agostinho, P.; Cunha, R.A.; Oliveira, C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr. Pharm. Des. 2010, 16, 2766–2778. [CrossRef] [PubMed]
13. Yang, W.; Xiong, G.; Lin, B. Cyclooxygenase-1 mediates neuroinflammation and neurotoxicity in a mouse model of retinitis pigmentosa. J. Neuroinflamm. 2020, 17, 306. [CrossRef] [PubMed]
14. Rawat, C.; Kukal, S.; Dahiya, U.R.; Kukreti, R. Cyclooxygenase-2 (COX-2) inhibitors: Future therapeutic strategies for epilepsy management. J. Neuroinflamm. 2019, 16, 1–15. [CrossRef] [PubMed]
15. Radu, B.M.; Epureanu, F.B.; Radu, M.; Fabene, P.F.; Bertini, G. Nonsteroidal anti-inflammatory drugs in clinical and experimental epilepsy. Epilepsy Res. 2017, 131, 15–27. [CrossRef]
16. Dhir, A. An update of cyclooxygenase (COX)-inhibitors in epilepsy disorders. Expert Opin. Investig. Drugs 2019, 28, 191–205. [CrossRef]
17. Suemaru, K.; Yoshikawa, M.; Tanaka, A.; Araki, H.; Aso, H.; Watanabe, M. Anti-convulsant effects of acetaminophen in mice: Comparison with the effects of nonsteroidal anti-inflammatory drugs. Epilepsy Res. 2018, 140, 22–28. [CrossRef]
18. Vieira, V.; Glassmann, D.; Marafon, P.; Pereira, P.; Gomez, R.; Coitinho, A.S. Effect of diclofenac sodium on seizures and inflammatory profile induced by kindling seizure model. Epilepsy Res. 2016, 127, 107–113. [CrossRef]
19. Akula, K.K.; Dhir, A.; Kulkarni, S.K. Rofecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor increases pentylenetetrazol seizure threshold in mice: Possible involvement of adenosinergic mechanism. Epilepsy Res. 2008, 78, 60–70. [CrossRef]
20. Zhou, L.; Zhou, L.; Cao, S.L.; Xie, Y.J.; Wang, N.; Shao, C.Y.; Wang, Y.-N.; Zhou, J.-H.; Cowell, J.K.; Shen, Y. Celecoxib ameliorates seizure susceptibility in autosomal dominant lateral temporal epilepsy. J. Neurosci. 2018, 38, 3346–3357. [CrossRef]
21. Dhir, A.; Naidu, P.S.; Kulkarni, S.K. Effect of naproxen, a non-selective cyclooxygenase inhibitor, on pentylenetetrazol-induced kindling in mice. Clin. Exp. Pharmacol. Physiol. 2005, 32, 574–584. [CrossRef]
22. Darvishi, H.; Rezaei, M.; Khodayar, M.J.; Reza Zargar, H.; Dehghani, M.A.; Rajabi Vardanjani, H.; Ghanbari, S. Differential effects of meloxicam on pentylenetetrazol-and maximal electroshock-induced convulsions in mice. Jundishapur J. Nat. Pharm. Sci. 2017, 12, e36412.
23. Babalho, P.G.; Carvalho, B.S.; Lopes-Cendes, I.; Maurer-Morelli, C.V. Cyclooxygenase-1 as a Potential Therapeutic Target for Seizure Suppression: Evidences from Zebrafish Pentylenetetrazole-Seizure Model. Front Neurol. 2016, 7, 200. [CrossRef]
24. Haroun, M.; Tratrat, C.; Kolokotroni, A.; Petrou, A.; Geronikaki, A.; Ivanov, M.; Kostic, M.; Sokovic, M.; Carazo, A.; Mladénka, P.; et al. 5-Benzyliden-2-(5-Methylthiazol-2-Ylimino)Thiazolidin-4-Ones as Antimicrobial Agents. Design, Synthesis, Biological Evaluation and Molecular Docking Studies. Antibiotics 2021, 10, 309. [CrossRef] [PubMed]
25. Omar, K.; Geronikaki, A.; Zoumpoulakis, P.; Camoutsis, C.; Soković, M.; Ćirić, A.; Glašočić, J. Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg. Med. Chem. 2010, 18, 426–432. [CrossRef]
26. Mishchenko, M.; Shtrygol, S.; Kukal, S.; Lesyk, R. Thiazole-bearing 4-thiazolidinones as new anticonvulsant agents. Sci. Pharm. 2020, 88, 16. [CrossRef]
27. Schadich, E.; Kryshchysyn-Dylevych, A.; Holota, S.; Polishchuk, P.; Džubak, P.; Gurska, S.; Hajduch, M.; Lesyk, R. Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds. J. Chem. Eng. Data 2020, 65, 107–113. [CrossRef]
28. Skyjarova, Y.; Fomenko, I.; Lozynska, I.; Lozynskyi, A.; Lesyk, R. Hydrogen sulfide releasing 2-mercaptoacrylic acid-based derivative possesses cytoprotective activity in a small intestine of rats with medication-induced enteropathy. Sci. Pharm. 2017, 85, 35. [CrossRef] [PubMed]
29. Liaras, K.; Fesatidou, M.; Geronikaki, A. Thiazoles and thiazolidinones as COX/LOX inhibitors. Molecules 2018, 23, 685. [CrossRef] [PubMed]
30. Mishchenko, M.V.; Shtrygol, S.Y.; Lesyk, R.B.; Lozynskyi, A.V.; Holota, S.M. Screening study of new thiazolidinone derivatives for anticonvulsant activity. Zaporizhje Med. J. 2020, 22, 840–846. (In Ukrainian)
31. Sarkis, G.Y.; Al-Azawe, S. Preparation and spectral characterization of substituted 2-aminothiazoles. J. Chem. Eng. Data 1973, 18, 99–102. [CrossRef]
32. Ostapiuk, Y.V.; Obushak, M.D.; Matiychuk, V.S.; Naskrent, M.; Gzella, A.K. A convenient method for the synthesis of 2-[(5-benzyl-1,3-thiazol-2-yl)iminio]-1,3-thiazolidin-4-one derivatives. Tetrahedron Lett. 2012, 53, 543–545. [CrossRef]
33. Subtel’na, I.; Atamanyuk, D.; Szymańska, E.; Kiec-Kononowicz, K.; Zimenkovsky, B.; Vasylenko, O.; Gzella, A.; Lesyk, R. Synthesis of 5-aryliden-2-amino-4-azolones and evaluation of their anticonvulsant activity. Bioorg. Med. Chem. Lett. 2010, 18, 5090–5102. [CrossRef] [PubMed]
34. Hock, F.J. Drug Discovery and Evaluation: Pharmacological Assays; Springer International Publishing: Cham, Switzerland, 2016; 431p.
35. Paronikyan, R.G.; Avagyan, M.N.; Harutyunyan, A.A.; Avakyan, G.G.; Litvinova, S.A.; Voronina, T.A. Experimental study of the anticonvulsant and psychotropic properties of pufemid, piratidine and N3212 in comparison with known antiepileptic drugs. Epilepsy Paroxysmal Cond. 2019, 11, 244–254. [CrossRef]
36. Oliveira, M.S.; Furian, A.F.; Royes, L.F.F.; Fighera, M.R.; Fiorenza, N.G.; Castelli, M.; Machado, P.; Bohrer, D.; Veiga, M.; Ferreira, J.; et al. Cyclooxygenase-2/PGE2 pathway facilitates pentylenetetrazol-induced seizures. Epilepsy Res. 2008, 79, 14–21. [CrossRef]
37. Bespalov, A.; Michel, M.C.; Steckler, T. Good Research Practice in Non-Clinical Pharmacology and Biomedicine; Springer: Cham, Switzerland, 2020; 423p.
38. SwissADME. Available online: http://www.swissadme.ch/ (accessed on 27 March 2021).
39. Katyal, J.; Kumar, H.; Gupta, Y.K. Anticonvulsant activity of the cyclooxygenase-2 (COX-2) inhibitor etoricoxib in pentylenetetrazol-kindled rats is associated with memory impairment. Epilepsy Behav. 2015, 44, 98–103. [CrossRef]